Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...
Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies. This is an ASCO ...
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for weight loss, to reduce the risk of serious cardiovascular problems, and to treat a serious liver problem called ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback